STELLA PHARMA CORPORATION (JP:4888)

:4888

4888

STELLA PHARMA CORPORATION

RESEARCH TOOLSreports

Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥18.01B

Enterprise Value¥15.75B

Total Cash (Recent Filing)¥2.85B

Total Debt (Recent Filing)¥727.12M

Price to Earnings (P/E)―

Beta0.98

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.00

Shares Outstanding35,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio1.10

Price to Book (P/B)3.99

Price to Sales (P/S)13.30

P/FCF Ratio93.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Robust Revenue GrowthSustained top-line expansion (nearly 10x in three years) indicates successful commercial traction or pipeline monetization. Durable revenue growth supports scale economics, enhances negotiating leverage with partners, and creates a stronger base to absorb R&D and SG&A as the company moves toward profitability.

Improved Cash GenerationTransitioning to positive operating and free cash flow signals improving cash conversion and operational efficiency. Sustainable cash generation reduces dependence on external financing, funds ongoing R&D/clinical activities, and provides flexibility for strategic investments or partnerships over the medium term.

Conservative Balance SheetA strong equity position and low debt provide a durable financial cushion to fund development and commercialization. This balance sheet strength lowers refinancing risk, supports long-term investment in pipelines or manufacturing, and makes the company a more credible partner for collaborations.

Bears Say

Persistent LossesOngoing net losses and negative EBIT are structural constraints that can erode equity over time and limit reinvestment capacity. Until the company demonstrates sustainable profitability or clear path to breakeven, it may face recurring funding needs and pressure on long-term financial resilience.

Weak Cash QualityA low ratio of operating cash flow to net income implies that reported losses are not yet translating into robust, high-quality cash generation. This mismatch raises concern about the durability of cash flows and could force reliance on equity or debt raises if operating conversion does not improve.

Limited Organizational ScaleA small headcount constrains internal capacity for commercial rollout, regulatory submissions, and multi-region manufacturing or trials. To scale operations or broaden market access, the company will likely need to hire or partner, both of which increase costs or dilute margins until scale is achieved.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥18.01B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Aug 12, 2026 which is in 101 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on Feb 12, 2026. The company reported -¥6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 35,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.814%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.